Abstract
Protein kinase C (PKC) has been known to play an important role in ischemic preconditioning (IP). This study was designed to examine whether the translocation of PKC is associated with the cardioprotective effects of IP in vivo on infarct size and ventricular arrhythmias in a rat model.
Using anesthetized rats, heart rate, systolic blood pressure, infarct size and ventricular arrhythmias during 45 min of coronary occlusion were measured. PKC activity was assayed in both the cytosolic and cell membrane fraction . Brief 3-min periods of ischemia followed by 10 min of reperfusion were used to precondition the myocardium. Calphostin C was used to inhibit PKC.
Infarct size was significantly reduced by IP (68.1 (2.5)%, mean (S.E.) vs. 45.2 (3.4)%, p < 0.01). The reduction in infarct size by IP was abolished by pretreatment with calphostin C. The total number of ventricular premature complex (VPC) during 45 min of coronary occlusion was reduced by IP (1474 (169) beats/45 min vs. 256 (82) beats/45 min, p < 0.05). The reduction the total number of VPC induced by IP was abolished by the administration of calphostin C before the episode of brief ischemia. The same tendency was observed in the duration of ventricular tachycardia and the incidence of ventricular fibrillation. PKC activity in the cell membrane fraction transiently increased immediately after IP (100 vs. 142%, p < 0.01) and returned to baseline 15 min after IP. Pretreatment with calphostin C prevented the translocation of PKC.
The translocation of PKC plays an important role in the cardioprotective effect of IP on infarct size and ventricular arrhythmias in anesthetized rats.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124–1136, 1986
Lawson CS, Downey JM: Preconditioning: State of art myocardial protection. Cardiovasc Res 27: 542–550, 1993
Cave AC, Hearse DJ: Ischemic preconditioning and contractile function: Studies with normothermic and hypothermic global ischemia. J Mol Cell Cardiol 24: 1113–1123, 1992
Schott RJ, Rohmann S, Braun ER, Schaper W: Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 66:1133–1142, 1990
Downey JM, Jordan M: Preconditioning limits infarct size in rabbits. Circulation 80(suppl H): (abstr) II-238, 1989
Alkhulaifi AM, Browne EE, Yellon DM: Ischemic preconditioning limits infarct size in the rat heart. J Mol Cell Cardiol 24(suppl 1): (abstr) S.93, 1992
Liu GS, Thornton J, Van Winkkle DM: Protection against infarction afforded by preconditionig is mediated by A I adenosine receptors in rabbit heart. Circulation 84: 350–356, 1991
Gross GJ, Auchampach JA: Blockade of ATP-sensitive potassium chan-nel prevents myocardial preconditioning in dogs. Circ Res 70: 223–233, 1992
Ytrehus K, Liu Y, Downey JM: Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 266 (Heart Circ Physiol): H1145–H1152, 1994
Piot CA, Padmanaban D, Ursell PC, Sievers RE, Wolfe CL: Ischemic preconditioning decreases apoptosis in rat hearts in vivo. Circulation 96: 1598–1604, 1997
Okamura T, Miura T, Iwamoto H, Shirakawa K, Kawamura S, Ikeda Y, Iwatate M, Matsuzaki M: Ischemic preconditioning attenuates apoptosis through protein kinase C in rat hearts. Am J Physiol 277: H1997–H2001, 1999
Kobayashi E, Nakano H, Morimoto M, Tamaoki T: Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159: 548–553, 1989
Selye H, Bajusz E, Grasso S et al.: Simple technique for the surgical occlusion of coronary vessels in the rat. Angiology 11: 398–407, 1960
Fishbein MC, Meerbaum S, Rit J et al.: Early phase acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium chloride staining technique. Am Heart J 101: 593–600, 1981
Walker MJ, Curtis MJ et al.: The Lambeth Conventions: Guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 22: 447–455, 1988
Vegh A, Szekeres L, Parratt JR: Preconditioning of the ischemic myocardium: Involvement of the L-arginine nitric oxide pathway. Br J Pharmacol 107: 648–652, 1992
Wall TM, Sheehy R, Hartman JC: Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 270: 681–689, 1994
Bell RM, Bums DJ: Lipid activation of protein kinase C. J Biol Chem 266: 4661–4664, 1991
Nisizuka Y: Studies and perspective of protein kinase C. Science 233: 305–312, 1986
Light PE, Sabir AA, Allen BG, Walsh MP, French RJ: Protein kinase C-induced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive, K channels, a possible mechanistic link to ischemic preconditioning. Circ Res 79: 399–406, 1996
Nisizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334: 661–665, 1988
Nishizuka Y: Intracellular signaling by hydrosis of phospholipids and activation of protein kinase C. Science 258: 607–614, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matsumura, K., komori, S., Takusagawa, M. et al. Protein kinase C is involved in cardioprotective effects of ischemic preconditioning on infarct size and ventricular arrhythmia in rats in vivo. Mol Cell Biochem 214, 39–45 (2000). https://doi.org/10.1023/A:1007119622322
Issue Date:
DOI: https://doi.org/10.1023/A:1007119622322